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Editorial Comment
Experimental Infarct Size
Reduction With Calcium
Channel Blockers*
ROBERT KLONER, MD, PHD, FACC,
KARIN PRZYKLENK, PHD
Los Angeles, California
The present study. Higginson et al. (1), in this issue of the
Journal, report on the effect of intracoronary diltiazem on
infarct size and contractile function in an anesthetized ca-
nine model of 90 min of left anterior descending coronary
artery occlusion followed by 4 h of reperfusion. Infusion of
diltiazem into the distal artery bed was initiated either
"early" (at the time of occlusion) or "late" (beginning
15 min before reperfusion) and maintained throughout the
initial 60 to 135 min of reflow . It is important to note that the
dose and rate of diltiazem infusion were chosen such that
hemodynamic variables and myocardial blood flow were not
altered by drug treatment. Higginson et al . (1) report that
both early and late infusion of diltiazem reduced the size of
the myocardial infarct.
These results are in general agreement with several
previous experimental studies (2) in which verapamil, nifed-
ipine and other calcium channel blockers were shown to
reduce myocardial infarct size in models of ischemia and
reperfusion. However, the efficacy of these agents clearly
depends on the experimental model used, the duration of
ischemia, the duration of reperfusion, the route of drug
administration and the length of time the drug is on board
.
For example, Reimer and Jennings (3) observed that intra-
venous verapamil reduced myocardial infarct size in a 40-
min model of occlusion and reperfusion but failed to reduce
infarct size when the duration of ischemia was extended
to 3 h
. Lo et al . (4) found that in a 3-h occlusion and 3-h
reperfusion protocol, intracoronary verapamilinfused dur-
ing ischemia and reperfusion reduced infarct size . In con-
trast, when intracoronary verapamil was administered only
during reperfusion, no reduction in infarct size was obtained .
It is well recognized that infarct size in the canine model
is highly dependent on the degree of collateral blood flow to
'Editorials published in Journal ofthe American College f Cardiology
reflect the views of the authors and do not necessarily represent the elews of
JACC or the American College of Cardiology.
From the Heart Institute Research Department, Hospital of the Sood
Samaritan and the Section of Cardiology, university of Southern California
Medical School . Los Angeles. California .
Address for morinti: Robert A. Matter, MD, PhD, The Heart Institute,
Hospital of the Good Samaritan, 616 South Witmer, Los Angeles, California
90017
.
01991 by
the American College of Cardiology
JACC Vol. 18, No . 3
Semember 1991 :876-8
the ischemic myocardium
; that is, for any given duration of
ischemia, there is a well documented inverse relation be-
tween extent of necrosis and myocardial blood flow during
occlusion (5). One puzzling aspect of the present study (1) is
the apparent absence of this relation between blood flow and
infarct size, even in the control group . Although the reasons
for this are unclear, it may be due to the uniformly high
values of collateral blood flow observed by Higginson et al .
(I) . In addition, the complex (and atypical) premeditation
and anesthetic regimen used in their study may have altered
the expected relation between blood flow and infarct size.
They observed that intracoronary diltiazem reduced infarct
size even when treatment was initiated shortly before reper-
fusion . This observation suggests that diltiazem may have
prevented so-called reperfusion injury-that is, injury at the
time of reflow, whereby myocytes reversibly injured at the
end of a period of ischenda become irreversibly damaged by
the act of reperfusion itself. However, the concept that
diltiazem prevented lethal reperfusion injury must be viewed
with caution because the agent was also present during the
final 15 min of ischemia .
Calcium channel Mockers and the stunned myocardium .
The second major finding reported by Higginson et al, (1) is
that early treatment with diltiazem enhanced recovery of
regional contractile function after reperfusion . Furthermore,
this enhanced segmental shortening in the subendocardium
occurred even in the presence of a small subendocardial
infarction . Because this improvement in function of the
"stunned myocardium" occurred without significant
changes in hemodynamics or regional myocardial blood
flow, these data suggest that diltiazem exerted a direct effect
on the remaining viable myocytes .
Using a 1S-min occlusion and reperfusion protocol, we
have observed improvements in function of stunned myo-
cardium with both verapamil (6) and nifedipine (7)
.
The
beneficial effects of intravenous verapamil were most strik-
ing when the agent was administered before and during
coronary occlusion and less striking when given only during
rpetfusion . However, nifedipine administered either intra-
venously or by an intracoronary i ,'rte (7) restored contrac-
tile function of the stunned myocardium to baseline preoc-
elusion values even when given after reperfusion .
Our data are similar to those of Higginson et al . (I) in that
a very small dose of intracoronary nifedipine restored wall
motion to essentially normal values without altering hemo-
dynamics or regional myocardial blood flow . Again, this
raises the Interesting possibility that the calcium channel
blacker was having a direct effect on the myocyte, rather
than simply exerting a peripheral hemodynamic or vascular
effect . In fact, Martian (8) demonstrated that the stunned
myocardium is characterized by an increase in calcium
transients and a decreased responsiveness of the myofila-
ments to calcium . Thus, it is possible that calcium antago-
nists reduce these calcium transients and improve the sen-
sitivity of the myofilaments to calcium .
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Clinical aspects of calcium channel blockers and acute
myocardial infarction. Although thrombolytic agents are un-
questionably the treatment of choice in acute myocardial
infarction, the search continues for adjuvant therapy that
will further improve the benefits of reperfusion . Aspirin .
heparin, beta-adrenergic blockers and angiotensin-convert-
ing enzyme inhibitors have all been used as adjuvant ther-
apy, with some modest success in improving clinical out-
come (9) .
Calcium channel blockers have consistently been shown
to be efficacious for the treatment of brief ischemic episodes
(that is, angina) ; however, their ability to improve outcome
associated with acute myocardial infarction has been disap-
pointing in most clinical studies (10-14) . Clinical studies
(10-14) performed in the 1980s (and before the standard use
of thrombolysis) found that calcium channel blockers neither
reduced myocardial infarct size nor improved survival
. In
patients with potential acute myocardial infarction or unsta-
ble angina . calcium channel blockers did not prevent myo-
cardial infarction (I1). Some studies did suggest. however,
that these agents might reduce reinfarction after non-Q wave
infarction (as shown with diltiazem) (15) and reduce postmy-
ocardial infarction angina (as shown with diltiazem and
nifedipine) (15
.16).
The feat trials that have assessed rite effects of calriroos
channel blockers as adjunctive therapy to thronbolvsislmre
also been disappointing . For example. Erbel et al
. (17)
failed to show improvement in left ventricular ejection
fraction or survival in patients who received nifedipine along
with thrombolysis for acute myocardial infarction . Ellis et al.
(18) reported the effects of long-term beta-adrenergic or
calcium channel blockade in patients who received coronary
angioplasty within 12 h of onset of symptoms of myocardial
infarction and found that patients receiving a beta-blocker at
the time of infarction had a lower mortality rate than those
not receiving a beta-blocker . In contrast . calcium channel
blockade did not affect survival .
Given the large number of experimental studies that have
documented a beneficial effect of calcium channel blockers
on infarct size and cardiac function in models of ischemia
and reperfusion, it is surprising that more clinical studies
have not addressed this issue
. Perhaps the major reason for
lack of enthusiasm in studying calcium channel blockers as
possible adjunctive therapy with thrombolysis is the nega-
tive studies in the 1980s and recent studies (19-21) showing
a wor;eoing of congestive heart failure with calcium antag-
onist therapy in instances of underlying left ventricular
dysfunction. It is unlikely that calcium channel blockers will
be used as standard adjunctive therapy in the selling of acute
Q wave myocardial infarction in the immediate future . At
present . these agents are not routinely recommended in
acute Q wave myocardial infarction and should be used only
if there is a specific indication such as postinfarction angina
and hypertension . Furthermore . they should be used with
great caution in patients with severe left ventricular dysfunc-
tion.
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What Factors might account for the apparent discrepancy
between animal studies that have shown reductions in infarct
size with calcium channel blockers and the general lack of
efficacy of these agents in patients with acute myocardial
infarction! It is possible that in some of the clinical studies,
too high a dose may have been used, resulting in decreased
coronary perfusion pressure . This reduction in blood pres-
sure may further result in reflex tachycardia. which could
increase the severity of ischemia . i n a ddition . it appears
likely that . in some instances, calcium channel blockers may
have stimulated neurohumoral mechanisms that may have
caused worsened heart failure (20) .
Effect of long-term calcium channel blacker therapy . Cal-
cium channel blockers have also been administered as main-
tenance therapy after acute myocardial infarction to deter-
nine whether they would enhance survival. In one study
(221, dihiazem administered on a long-term basis after in-
farction failed to improve overall survival . In fact, subgroup
analysis revealed that patients in the diltiazem group with
underlying pulmonary congestion had a higher cardiac event
rate than untreated patients. perhaps because of its negative
inotropic effect . However . patients without pulmonary con-
gestion did demonstrate an improved outcome . Similarly, in
a trial 1121 utilizing the cacicm channel blocker nifedipine,
there was no dttference in 10-month mortality or nonfatal
reinfarction rates between treated and untreated patients . In
contrast. the recent Danish Vempamil lnfaretisn Trial II
(DAVIT 11) 1241 reported a nonsignificant trend toward lower
mortality and significant reduction in major cardiac events in
patients who received verapamil beginning 2 weeks after
infarction . Of n ote . in
patients without heart failure while in
the coronary care unit . verapamil reduced the mortality rate
significantly from 11 .8% in the placebo group to
7 .7% in the
verapamil group (p = 0
.021 . However. there was no differ-
ence in mortality or major event rates with •terapamil in
patients with heart failure . Thus, alttough the results from
these three major trials are not definitive, data from DAVIT
It raise the possibility that verapamil may limit the incidence
of major cardiac events after myocardial infarction .
Implications
. Although clinical studies have, in general,
not shown calcium channel blockers to be capable of reduc-
ing infarct size or improving survival after infarction, exper-
imental data (6,7) suggest that these agents may improve
function of the stunned myocardium in patients who puffer
from briefer episodes of ischemia, such as patients eith
angina . Stunned myocardium has been described (25) both in
patients with unstable angina and in those with chronic
stable angina after exercise testing
. Although this issue
remains to be investigated, experimental results imply that
calcium channel blockers may be more likely to improve
regional wail motion abnormalities in the setting of brief
ischemia than in acute myocardial infarction
.
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